Lv21
154 积分 2025-02-08 加入
Iparomlimab and Tuvonralimab: First Approval
4天前
已完结
Cadonilimab: First Approval
1个月前
已完结
85P Tislelizumab combined with apatinib and oxaliplatin plus S1 as neoadjuvant therapy for Borrmann IV large Borrmann III type and bulky N positive advanced gastric cancer: A single-arm multicenter trial (TAOS-3B-Trial)
1个月前
已完结
Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2-Positive Locally Advanced Resectable Gastric Cancer
1个月前
已完结
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study
1个月前
已完结
Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types
1个月前
已完结
Diagnostic, Prognostic, and Predictive Biomarkers in Gastric Cancer: from Conventional to Novel Biomarkers
1个月前
已完结
Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors—A phase 1/1b study
1个月前
已完结
1414P Iparomlimab and tuvonralimab (QL1706) with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: An open-label phase II study
1个月前
已完结
Iparomlimab and Tuvonralimab: First Approval
1个月前
已完结
皖公网安备34019202002308
